T-Cure Bioscience Signs Exclusive Worldwide License With NCI for the Development of T Cell Receptor Therapy for Treatment of Solid Tumors

LOS ANGELES--(BUSINESS WIRE)--T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into an exclusive, worldwide license with the National Cancer Institute (NCI) for intellectual property related to a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1 (KK-LC-1), for the treatment of KK-LC-1-expressin

Click to view original post